Zhitong Finance App News, Xianjian Technology (01302.HK) issued an announcement. On September 24, 2026, the company received an official written notice from the State Drug Administration confirming that the sureCham™ aortic arch single-branch laminating stent system (sureCham™ single-branch stent or “this product”), which was jointly developed by the Company and Professor Shu Chang's team at Fuwai Hospital of the Chinese Academy of Medical Sciences of the National Cardiovascular Center, has entered the Special Review Procedure for Innovative Medical Devices by the State Drug Administration (this procedure). This product is suitable for treating aortic dissection involving the active arch. It is the company's 19th product to enter this procedure by the State Drug Administration.

Zhitong Finance App News, Xianjian Technology (01302.HK) issued an announcement. On September 24, 2026, the company received an official written notice from the State Drug Administration confirming that the sureCham™ aortic arch single-branch laminating stent system (sureCham™ single-branch stent or “this product”), which was jointly developed by the Company and Professor Shu Chang's team at Fuwai Hospital of the Chinese Academy of Medical Sciences of the National Cardiovascular Center, has entered the Special Review Procedure for Innovative Medical Devices by the State Drug Administration (this procedure). This product is suitable for treating aortic dissection involving the active arch. It is the company's 19th product to enter this procedure by the State Drug Administration.